Biotech Company With Clinical Operations Developing Psychedelic Medicine To Treat Addiction

First 3 UK Clinics Opening In September, Targeting 20 Clinics By 2024 ~$100M In Revenue

Sponsored
Message: VIDEO - Awakn Life Sciences Corp. (AWKN: NEO) Is Addressing The Multi-Billion Dollar Addiction Treatment Industry With Psychedelics

VIDEO - Awakn Life Sciences Corp. (AWKN: NEO) Is Addressing The Multi-Billion Dollar Addiction Treatment Industry With Psychedelics

posted on Jun 22, 2021 07:42PM

To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.  

Awakn has a dual strategic focus: 

  1. Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
  2. Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally. 

Notable Highlights include: 

  • Strategic focus on better treating Addiction with psychedelics.
  • World leading team focused on psychedelic drug and therapy research. 
  • Strong drug and therapy development pipeline, specifically targeting Addiction.
  • Clinics, which will be the UK and EU’s leading medical psychedelic therapy delivery 
  • Closed $8.3M June 8
  • BRAND NEW LISTING … commencing trading on NEO

Sit back, relax and watch this powerful interview with CEO Anthony Tennyson. 

Share
New Message
Please login to post a reply